237 related articles for article (PubMed ID: 8391739)
1. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
2. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
Hinuma S; Hazama M; Mayumi A; Fujisawa Y
FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
[TBL] [Abstract][Full Text] [Related]
4. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
5. Role of coexpression of IL-2 and herpes simplex virus proteins in recombinant vaccinia virus vectors on levels of induced immunity.
Allen EM; Weir JP; Martin S; Mercadal C; Rouse BT
Viral Immunol; 1990; 3(3):207-15. PubMed ID: 2175194
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
8. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
Weinberg A; Merigan TC
J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
[TBL] [Abstract][Full Text] [Related]
10. The effect of immunization with herpes simplex virus glycoprotein D fused with interleukin-2 against murine herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Inoue Y; Tano Y; Shimomura Y; Fujisawa Y; Aono A; Hayashi K
Jpn J Ophthalmol; 2002; 46(4):370-76. PubMed ID: 12225814
[TBL] [Abstract][Full Text] [Related]
11. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
14. Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens.
Karem KL; Bowen J; Kuklin N; Rouse BT
J Gen Virol; 1997 Feb; 78 ( Pt 2)():427-34. PubMed ID: 9018066
[TBL] [Abstract][Full Text] [Related]
15. Virus neutralizing activity induced by synthetic peptides of glycoprotein D of herpes simplex virus type 1, selected by their reactivity with hyperimmune sera from mice.
Geerligs HJ; Kocken CH; Drijfhout JW; Weijer WJ; Bloemhoff W; Wilterdink JB; Welling GW; Welling-Wester S
J Gen Virol; 1990 Aug; 71 ( Pt 8)():1767-74. PubMed ID: 2167930
[TBL] [Abstract][Full Text] [Related]
16. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
Dix RD; Mills J
J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
18. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins.
Nass PH; Elkins KL; Weir JP
J Infect Dis; 1998 Sep; 178(3):611-7. PubMed ID: 9728527
[TBL] [Abstract][Full Text] [Related]
19. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
Rooney JF; Wohlenberg C; Cremer KJ; Moss B; Notkins AL
J Virol; 1988 May; 62(5):1530-4. PubMed ID: 2833606
[TBL] [Abstract][Full Text] [Related]
20. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D.
Wachsman M; Aurelian L; Smith CC; Lipinskas BR; Perkus ME; Paoletti E
J Infect Dis; 1987 Jun; 155(6):1188-97. PubMed ID: 3033094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]